Clinical Trial

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-13; most recent amendment 2026-05-22.
Status change: Not Yet Recruiting → Recruiting 2025-12-28
Trial Details
NCT Number NCT07131514
Lead Sponsor Ruijin Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Pancreatic Cancer
Enrollment 30 participants
Start Date 2025-08-25
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27